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enrolment and at end of therapy (EOT). Among 159 DFI episodes, 93 involved the bone and 66 the soft
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(median 67 vs. 81 mg/L) or EOT (7 vs. 10 mg/L). Similarly, there was negligible difference in the
percentage of CRP levels that normalized at EOT (39% vs. 35%). In our prospective cohorts, a blunt
iterative monitoring of CRP during DFI treatment, without correlation with clinical findings, failed to
predict treatment failures.
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Clinicians frequently monitor serum C-reactive protein (CRP) levels during the therapy 
of diabetic foot infections (DFI), but evidence supporting this is unclear. Using a 
database from prospective-controlled DFI trials, with fixed duration of antibiotic 
therapy, we correlated the CRP levels at study enrollment and at end of therapy (EOT). 
Among 159 DFI episodes, 93 involved the bone and 66 the soft tissues. Overall, 
treatment cured 122 infections (77%), while 37 episodes (23%) recurred after a median 
of 53 days. The median CRP in the groups with cure versus recurrent infection differed 
minimally at enrollment (median 67 mg/L vs. 81 mg/L) or EOT (7 mg/L vs. 10 mg/L). 
Similarly, there was negligible difference in the percentage of CRP levels that 
normalized at EOT (39% vs. 35%). In our prospective cohorts, a blunt iterative 
monitoring of CRP during DFI treatment, without correlation with clinical findings, 
failed to predict treatment failures. 




Clinicians frequently monitor serum C-reactive protein (CRP) levels1,2 during the 
treatment of diabetic foot infections (DFI). This is usually in hopes of assessing the 
evolution of infection, attempting to provide a prognosis, or being forewarned of 
problems. Unfortunately, failure of CRP levels to fall may trigger unnecessary 
diagnostic studies (imaging, angiology procedures, additional cultures) or therapeutic 
interventions (altering antibiotic therapy, surgical or adjunctive treatments), even in 
absence of clinical indications. Of particular concern in this era of growing antibiotic 
resistance is the unnecessary broadening or prolongation of the antibiotic regimen based 
more on CRP levels3 than clinical findings4. Evidence for the value of monitoring CRP 
in DFI patients remains unclear, especially since the CRP peak almost always lags 
behind the clinical evolution by about two days1,5. While some scientific literature 
supports using the quantitative serum CRP level in diagnosing the presence or severity 
of a DFI1,4-7, infectious diseases experts generally emphasize that no therapeutic 
decision should depend solely on this laboratory result8,9. We undertook this study to 
provide more information based on the utility of routine serum CRP controlling during 
DFI therapy. In contrast we not address the role of the serum CRP in the diagnosis of 
DFI, including for the diagnosis DFO, for which a broader literature is available8. 
 
METHODS AND STUDY AIMS  
Setting 
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At the Geneva University Hospitals, we performed two prospective-comparative trials, 
randomizing patients with DFIs to fixed durations of antibiotic therapy after (surgical) 
debridement (Ethical Committee BASEC 2016-01008). We assigned the duration of 
antibiotic therapy to either a short arm (10 days for soft tissue infections; 3 weeks for 
diabetic foot osteomyelitis [DFO]) and a long arm (20 days for soft tissue DFIs and 6 
weeks for DFO); without crossovers throughout the trials.  
 
Processing of the serum CRP 
This database we assembled from these prospective studies allowed us to assess the 
predictive role of obtaining iterative serum CRP samples (or their dynamic change) on 
the likelihood of clinical treatment failure. The study treatment period included the 
following visits, whether as an inpatient or outpatient: Enrollment (Day 1); Day 10 (± 2 
days); Day 20 (± 2 days); Day 42 (only if still receiving antibiotic therapy). The test-of-
cure (TOC) visit occurred at 60 days (± 10 days) after the end of treatment (EOT). The 
CRP values were measured at enrollment and at the EOT, sometimes during each visit 
and sometimes between the visits at the discretion of the treating clinicians. According 
to the protocol of the randomized trials, which was based on standard advice for daily 
practice, CRP measurements were not required if all aspects of the patient's infection were 
stable or improving. We processed all serum CRP samples in our laboratory. A CRP-test 
cost 10 Swiss Francs (10 US $) and a value <10 mg/L was within the laboratory norms.  
 
Statistical analyses 
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The primary outcome for this study was remission of DFI at the EOT visit, which we 
correlated with the serum CRP levels at study enrolment and at the TOC visit. We 
assessed whether or not baseline and EOT-CRP levels can be used to predict future 
treatment failure. For group comparisons we used the Pearson- 2, the Wilcoxon-
ranksum, or the t-test, as appropiate. As this study was a side study, we did not 
determine any formal sample size requirement, as, moreover, the number of CRP 
samples collected was greater than the number of DFI episodes of the randomized 
studies. We used STATA™ software (15.0; College Station, Texas, USA) and assigned 




We enrolled 159 DFI episodes in the two trials: 93 DFO and 66 the soft tissue 
infections. Among the 159 episodes, 80 were treated with a short duration of antibiotics, 
and 79 a long duration. Overall, 122 episodes (77%) were clinically cured and 37 (23%) 
were failures, after a median of 53 days post-treatment. When stratified, the overall 
remission was 84% in the DFO group (44 episodes) with a short arm versus 73% in the 
DFO group with the long antibiotic arm (49 episodes). Regarding the 66 soft tissue 
DFIs, the cure incidences were 77% and 71%, respectively. All patients had CRP 
sampling, wound care, off-loading; and angioplasty in 21 cases. The minimal follow-up 
duration was 2 months after EOT, but the real active median follow-up time was 1 year. 
The most frequent pathogen was Staphylococcus aureus in 65 episodes (41%). 




Association of clinical outcome with serum CRP levels 
Although the CRP levels in the failed episodes were very slightly higher at both 
enrollment and at the EOT (absolute differences of 8-14 mg/L and 3-4 mg/L, 
respectively), the median CRP values at both time points (enrolment and EOT) were not 
statistically different (Table 1). Similarly, the same proportion patients of achieved 
normalization of their CRP values (i.e. drop to less than 10 mg/L) at the EOT (39% vs. 
35%, Table 1). Equally, the relative drop (ratio of final CRP values divided by the 
admission level) was the same (median drop of 67% vs. 63%, Table 1). Table 1 




Using data from two randomized trials with fixed antibiotic therapies for DFIs, we 
found no association between the initial (enrollment) and final (EOT) serum CRP 
samples values and treatment failure. The variance of the results was high, implying a 
very large distribution of various CRP levels in the different strata (Figure 1). This 
finding was true for all strata: median values at enrollment and at EOT; the number of 
CRP values that normalized (<10 mg/L); or, the relative decrease in CRP values during 
therapy for DFI. These findings cast doubt on the widely-held view that following 
levels of CRP during therapy of DFIs helps predict the clinical outcome. In reality, 
measuring the CRP probably adds little or nothing to careful clinical assessment. 




There are only few prospective studies examining the performance of CRP for the 
follow-up of DFOs. Michail et al. sampled various serum inflammatory markers in 61 
patients with DFO after 1 week, 3 weeks, and 3 months of treatment1 and found that all 
values declined after initiation of antibiotic therapy. Specifically, the CRP values 
returned to near-normal levels at Day 21, but their results did not clarify if there was 
any clinical benefit to routinely monitoring the CRP, or what that added to just careful 
clinical evaluation1. Similarly, Van Asten et al. measured CRP levels (along with other 
markers) in 35 patients with an infected diabetic foot ulcer at baseline, and after 3 and 6 
weeks of antibiotic therapy2. They found that almost all values decreased in patients 
with a good outcome, but they provided no comparative analysis on the CRP values2. 
 
In the elderly population, in which DFIs are most common, the serum CRP levels are 
dynamic and influenced by many co-morbidities such as gout10,11, cancer10, rheumatic 
diseases10, thrombosis9, obesity9-11, statins11, hematoma12, ischemia11, dialysis7, 
cirrhosis13, or the postoperative state5. Also, the presence of diabetes itself may cause a 
slight elevation of CRP level11. Finally, CRP peak levels generally lag 2-3 days behind 
the causative events, making a timely interpretation impracticable5,13. 
 
The results of studies of routine serial serum CRP levels are equally reported in other 
fields of orthopedic surgery. Dupont et al monitored arthroplasties and concluded that 
local wound discharge, body temperature and pain are more informative indicators of 
This ar icle is pro ec ed b  cop righ  All righ s reser ed
 
 
postoperative infection than the evolution of the CRP14. Similarly, Bejon et al evaluated 
260 infected arthroplasties with 3732 CRPs and found that the CRP was a poor 
predictor of outcome15. Their area under the ROC curves for the CRP levels predicting a 
good outcome ranged from 0.55 to 0.65, thus only slightly better than a coin toss15. 
 
Our study has two main strengths: the large population makes it statistically well-
powered and it is based on a prospective database. It has also important limitations.  
First, the CRP samples were collected as a sub-study. A randomized-controlled trial 
designed to assess the routine use of CRP as its primary objective would gather 
additional data, such as discontinuing antibiotic therapy after the normalization of the 
CRP. While such a trial would be innovative, it is not realistic. For DFI the total 
duration of antibiotic therapy is determined by expert opinion8 (often codified in 
guidelines) based on few data9, and not on a single laboratory parameter8.9.  
Second, we are unable to assess which additional clinical examinations were triggered 
by an unexpectedly elevated CRP level. Although we have a comprehensive database 
documenting regular medical and nursing care and validated case report forms, we 
cannot determine if the motivation of the individual clinician for ordering a specific 
additional examination was related to noting an elevated CRP level.  
Third, we determined only the standard laboratory test for serum CRP. Thus, our 
findings may not apply to other inflammatory markers, such as pro-calcitonin2,4,5, 
erythrocyte sedimentation rate2,4,6, interleukins 2, 6 or 82,4, serum leukocyte counts4, 
tumor necrosis factors2,4, monocyte chemotactic protein4, macro-phage inflammatory 
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protein-1 alpha4, neutrophil to lymphocyte ratios6, procollagen type 1 N propeptides2,4, 
or high-resolution CRPs. However, these other markers are seldomly used in daily 
clinical practice and all are more expensive than the standard CRP. Likewise, the 
potential heterogeneity of the factors (such as interventional procedure, additional 
comorbidity or different treatments) and the fact that CRP values were not compared 
with other infectious parameters might impair the universality of the result. We need 
other studies to identify the accuracy of different biomarkers in DFI therapy. 
 
In conclusion, in our prospectively-collected database, collecting routine CRP samples, 
at different time points during ongoing therapy for DFI, failed to predict the clinical 
outcomes. Based on these results, and our review of the available literature, we 
recommend abandoning ordering such routine CRP level. Ordering these clinically 
unhelpful samples wastes money, leads to unnecessary discomfort and time-expenditure 
associated with phlebotomies for patients and nurses, and often leads to further 
unneeded and excessive diagnostic evaluations.  
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Figure 1: Median serum C-reactive protein values at enrollment and at end of 
treatment; stratified between non-infectious complications and infections. 
The bars in the middle of the columns represent the 95% confidence intervals. Of note, 
these intervals are very wide and many patients (35-39%) yielded baseline CRP values 
between 1-10 mg/L (normal range of our laboratory). 
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